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Acute ataxia in childhood is often caused by toxin 
ingestion. With the increasing number of paediatric 
patients on antiretroviral medication, we observe 
more side-effects of these drugs. We report two 
separate cases of efavirenz toxicity that caused ataxia.
Background
A child presenting with ataxia may pose a diagnostic dilemma. After 
excluding the common causes, e.g. toxins, infection and tumours, 
one needs to consider, more carefully, a possible genetic cause, but 
with limited genetic testing facilities available in South Africa (SA) a 
definitive answer is not always found. 
It is estimated that there are 360 000 HIV-positive children <15 years 
of age in SA,[1] 44% of whom are on antiretroviral therapy (ART).[2] 
These patients often pose unique diagnostic challenges.
We treated two children who presented in a 1-month period, 
which highlighted an important differential to consider in HIV-
positive paediatric patients presenting with ataxia.
Case 1
A 6-year-old girl presented with acute onset of confusion, vomiting 
and difficulty walking. She was HIV-positive and had been on first-
line ART (abacavir, lamivudine and efavirenz) for the past year. The 
antiretrovirals were dosed appropriately according to the child’s 
weight and the Southern African HIV Clinicians Society guidelines. 
Her viral load 1 month before admission was <100 RNA copies/mL 
and her CD4 count 250 cells/µL.
There was no history of toxin ingestion. 
On examination she was markedly ataxic, unable to walk or sit 
unsupported, and was noted to have titubation, dysmetria and dys-
diadochokinesia.
Investigations for a possible infectious cause were done. The 
lumbar puncture (LP) was normal and serology for Varicella was 
negative; however, a CT scan of her brain was suggestive of possible 
cerebelitis. Although the cerebellar signs started acutely, they continued 
for >2 weeks. We therefore investigated further for possible inherited causes 
of progressive chronic ataxia. Our differential diagnosis included 
ataxia telangiectasia (no telangiectasia were present clinically and 
the immunoglobulin levels were normal), abetalipoproteinaemia, 
Friedreich’s ataxia and spinocerebellar ataxia, but genetic testing was 
negative. 
A magnetic resonance imaging (MRI) scan to better delineate the 
posterior fossa structures revealed a normal brain.
We considered medication toxicity because of the vomiting and the 
persistent ataxia. Therefore, an efavirenz level was determined and found 
to be 69 100 ng/mL (target trough concentration: 1 000 ng/mL). On 
discontinuing the efavirenz the patient showed signs of clinical 
improvement, with resolution of the vomiting and ataxia. A protease 
inhibitor was not started as the elevated efavirenz levels were 
expected to act as the third antiretroviral agent.
A repeat efavirenz level 7 days after discontinuing the drug showed 
persistently high levels (49  000 ng/mL), but the patient was able 
to walk unsupported and the dysmetria and dysdiadochokinesia 
had improved. We decided to administer lopinavir/ritonavir to the 
patient, and a month after discontinuing efavirenz she showed no 
residual cerebellar signs.
Case 2
A 13-year-old girl was referred to the paediatric neurology clinic with 
acute onset of an ataxic gait.
She was diagnosed with HIV 3 years previously and staged as 
World Health Organization clinical stage IV, but because of social 
issues was only started on ART (abacavir, lamivudine and efavirenz) 
18 months before her referral to the neurology department. The 
doses of antiretrovirals were all appropriate for her weight, according 
to the Southern African HIV Clinicians Society guidelines. When she 
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presented with ataxia she was virally suppressed, with an HIV viral 
load of 28 RNA copies/mL and a CD4 count of 554 cells/µL.
On examination, she had a broad-based gait. Other cerebellar signs 
included dysmetria, dysdiadochokinesia and mild staccato speech, 
but no nystagmus.
Initial investigations were done to determine a possible infective 
cause. The LP was normal, and Varicella serology was negative. An 
MRI scan of her brain showed no intracranial lesions, structural 
changes or features of infection. 
Before investigating further and because of our experience in the 
first case, we considered possible efavirenz toxicity – the level was 
16 274 ng/mL.
Three weeks after discontinuing the drug, and relying on the 
elevated efavirenz levels to continue to act as the third antiretroviral 
agent, the efavirenz level had decreased to 1 002 ng/mL, with clinical 
improvement in her gait and resolution of her dysmetria. It was 
decided to opt for lopinavir/ritonavir as her third antiretroviral agent, 
and efavirenz was discontinued.
Efavirenz drug level methodology in 
both cases
Efavirenz is administered as a once-daily dose given at night to 
ameliorate its potential neurological side-effects. In both of the 
children reported here, drug levels were collected during the day, 
before 12h00. Blood samples were collected in a 5 mL heparinised BD 
Vacutainer vial (BD Plymouth, UK). Specimens were stored at 2 - 8˚C 
until analysed. Analysis was performed using liquid chromatography-
tandem mass spectrometry (LC-MS MS) at Ampath’s laboratory in 
Johannesburg. An LC-MS MS TQD (triple quad detector) instrument 
from Waters in electrospray positive ionisation mode was used, 
employing an external standard from ChromSystems (Multilevel 
Plasma Calibrator Set Anti-HIV Drugs) for quantitation. Efavirenz 
is identified according to the molecular mass of its parent ion 316, as 
well as one daughter ion of molecular mass 244, and retention time.
Discussion
Acute ataxia is defined as unsteadiness of walking or fine motor 
movement of <72 hours. The most common causes are postinfectious 
acute cerebellar ataxia, toxin ingestion and Guillain-Barré syndrome.[3] 
However, the possibility of a mass lesion must always be excluded.
Reported neurological abnormalities in HIV-positive children 
range from 10% to 68%.[4] An SA study found the prevalence of 
neurological complications to be 59%, the most common of which 
were HIV encephalopathy and long-tract motor signs; however, no 
cases of cerebellar dysfunction were documented.[4] The occurrence 
of ataxia in an HIV-positive person is rare, the chronic sequelae being 
neurocognitive impairment and polyneuropathy.[5] 
Ataxia in the setting of HIV is generally secondary to an infectious, 
vascular or neoplastic cerebellar lesion. Most infections are opportunis-
tic and unlikely to occur when the CD4 count is adequate.[5] The 
vascular or mass lesions are readily excluded with neuro-imaging. 
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that 
disrupts HIV replication by inhibiting the reverse transcriptase 
enzyme. Efavirenz is known to have good central nervous system 
(CNS) penetration[6] and because of its long half-life is administered 
as a once-daily dose. The drug forms part of the SA first-line ART 
regimen for children >3 years of age and >10 kg in weight.[7]
CNS symptoms are the most frequently reported side-effects in 
HIV-positive patients on efavirenz, including dizziness, headache, 
confusion, stupor, impaired concentration, agitation, amnesia, 
depersonalisation, hallucinations, insomnia and abnormal dreams.[6,8-14] 
The frequency of CNS side-effects is estimated at 20 - 40%.[10] The majority 
of patients develop CNS and psychiatric adverse effects in the first 6 weeks 
of treatment,[11] with most symptoms resolving 6 - 10 weeks after treatment 
initiation.[6] Hoffmann et al.[12] documented neurocerebellar side-effects in 
patients using efavirenz. These symptoms were based on patient self-
reported dizziness, ataxia, insomnia, bad dreams and hallucinations 
– there was no objective assessment of the ataxia. The neurocerebellar 
symptoms were again reported to occur most frequently in the first 
month of initiating efavirenz and declined with time.[12]
Many studies have examined the effect of efavirenz drug levels 
on the frequency of side-effects. Marzolini et al.[10] reported a 24% 
increase in CNS side-effects if the plasma level was >4 000 ng/mL; 
however, other research groups have found no correlation between 
adverse effects and plasma concentrations.[8,9,13] Gutierrez et al.[13] 
showed that CNS side-effects associated with long-term efavirenz 
administration were related to efavirenz plasma levels. 
Wide variations in the plasma levels of patients on the same 
weight-appropriate dose of efavirenz have been demonstrated. One 
of the causes attributed to this individual variation in efavirenz 
levels is polymorphism of the CYP2B6 metabolising enzyme of the 
cytochrome P450, as efavirenz is a substrate of this enzyme.[9] A study 
done in Botswana found that the prevalence of the slow metabolising 
genotype was 30%, and other studies have also shown a higher 
incidence of this genotype in African populations.[14] 
We conclude that the cause of ataxia in both our patients was 
attributable to the high plasma concentration of efavirenz. In both 
cases, the efavirenz level was at least 4 times greater than the toxic 
level (4 000 ng/mL) described by Marzolini et al.,[10] and the ataxia 
improved when the drug was discontinued. Polymorphism of the 
CYP2B6 enzyme is a possibility in our patients, and may explain the 
very high plasma levels. 
When presented with a child with acute progressive ataxia, who is 
known to be on efavirenz, and after excluding the common causes, 
one should check the efavirenz plasma levels and, if toxic, consider 
discontinuing the agent and substituting it with an alternative class 
of antiretroviral drug. 
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